C12Y 502/01008
Peptidylprolyl isomerase , i.e. cyclophilin
Official title: Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
C12Y502/01008 (Peptidylprolyl isomerase , i.e. cyclophilin) appears on 141 US grants and 271 published applications in this corpus.
Search patents in C12Y- Granted patents
- 141
- Published applications
- 271
- Assignees
- 119
- Inventors
- 423
- Latest grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 0 |
| 2004 | 0 | 2 |
| 2005 | 0 | 8 |
| 2006 | 3 | 2 |
| 2007 | 1 | 13 |
| 2008 | 1 | 17 |
| 2009 | 10 | 12 |
| 2010 | 13 | 11 |
| 2011 | 6 | 3 |
| 2012 | 3 | 4 |
| 2013 | 1 | 6 |
| 2014 | 1 | 9 |
| 2015 | 4 | 10 |
| 2016 | 13 | 21 |
| 2017 | 8 | 15 |
| 2018 | 10 | 19 |
| 2019 | 12 | 19 |
| 2020 | 12 | 17 |
| 2021 | 9 | 8 |
| 2022 | 7 | 13 |
| 2023 | 1 | 17 |
| 2024 | 7 | 17 |
| 2025 | 9 | 18 |
| 2026 | 4 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Guided microbial remodeling, a platform for the rational improvement of microbial species for agriculture28 Apr 2026US 12,612,639 B2Pivot Bio, Inc.
- Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases17 Mar 2026US 12,576,140 B2The United States Government as Represented by the Department of Veterans Affair
- CD33 targeted immunotherapies17 Feb 2026US 12,552,855 B2Inhibrx Biosciences, Inc.
- Compositions and methods for enhanced protein production in bacillus licheniformis27 Jan 2026US 12,534,716 B2Danisco US Inc.
- Cognate foldase co-expression9 Dec 2025US 12,492,391 B2Novozymes A/S
- Chimeric receptors8 Oct 2026US 2026/0306631 A1St. Jude Children?S Research Hospital
- Lentiviral delivery of anti-cd20 chimeric antigen receptors8 Oct 2026US 2026/0308622 A1
- Mutant prolyl isomerase and glutamate-based amino acid production method using same13 Aug 2026US 2026/0234598 A1Cj Cheiljedang Corporation
- Uropathogenic escherichia coli recombinant protein composition ls, construction, expression, and purification method therefor, and use thereof30 Jul 2026US 2026/0218156 A1Zhejiang Chinese Medical University
- Recombinant retroviruses, compositions, and methods of use30 Jul 2026US 2026/0218229 A1Kelonia Therapeutics, Inc.
Most cited
By later US patents
- Functional and hyperfunctional siRNA230US 7,691,997 B2Dharmacon, Inc. · 2010
- Functional and hyperfunctional siRNA178US 8,090,542 B2Dharmacon, Inc. · 2012
- siRNA targeting KRAS90US 7,507,811 B2Dharmacon, Inc. · 2009
- siRNA targeting DNA-damage-inducible transcript 4 (DDIT4)87US 7,655,788 B2Dharmacon, Inc. · 2010
- Functional and hyperfunctional siRNA directed against Bcl-273US 7,511,132 B2Dharmacon, Inc. · 2009